Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer


This is a Phase I/IIa study evaluating the safety and feasibility of [89Zr]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer. Individuals participating in this study will have a FDG PET scan, as well as four (4) PET scans (over a 3 day period) following the injection of [89Zr]Df-IAB2M PET tracer. Three different dosing levels will be explored. The purpose of the study is to demonstrate the safety of [89Zr]Df-IAB2M, ability to detect prostate cancer, and optimal time point and dose level for imaging.

Full Title of Study: “A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2016

Detailed Description

IAB2M is an approximately 80 kDA molecular weight antibody fragment (a "Minibody"). Limited (Phase 0/Proof-of-concept) patient experience with this biologic targeting agent has been previously obtained with SPECT imaging Ex-US, demonstrating targeting of soft tissue and bone lesions in advanced metastatic prostate cancer.


  • Biological: [89Zr]Df-IAB2M
    • A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.

Arms, Groups and Cohorts

  • Experimental: [89Zr]Df-IAB2M
    • A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).

Clinical Trial Outcome Measures

Primary Measures

  • Determine the safety of [89Zr]Df-IAB2M PET in patients with metastatic prostate cancer.
    • Time Frame: Day 1 (Infusion Day) through Day 7
    • To assess the safety of a single dose of of [89Zr]Df-IAB2M

Secondary Measures

  • [89Zr]Dr-IAB2M PET/CT quantitative assessment of metastatic prostate cancer
    • Time Frame: Day 1 (Infusion Day) to Day 3
    • To determine the ability of 89Zr-Df-IAb2M PET to detect known sites of disease in patients with metastatic prostate cancer
  • Optimal parameters for imaging with [89Zr]Df-IAB2M
    • Time Frame: Day 1 (Infusion Day) to Day 3
    • To evaluate the mass dose and hours post infusion that provides optimal detection of metastatic prostate cancer
  • Sensitivity of [89Zr]Df-IAB2M to detect metastatic prostate cancer
    • Time Frame: Up to 4 weeks
    • To compare the results of the biopsy and FDG PET scan to the [89Zr]Df-IAB2M images

Participating in This Clinical Trial

Inclusion Criteria

  • Adult male >/= 18 years of age – Patients with histologically confirmed prostate cancer – Progressive disease manifest (within 6 weeks of screening) by either – imaging modalities (bone scan, MRI or CT) OR – biochemical progression (PSA) – Performance status of 60 or higher on Karnofsky scale – Subject's schedule permits compliance with all study procedures – Ability to understand and willingness to sign a written informed consent form Exclusion Criteria:

  • Previous anaphylactic reaction to huJ591 antibody or FDG imaging – On any new anticancer therapy (GnRH analog allowed) while on the study – Hepatic lab values: Bilirubin>1.5 ULN; AST/ALT >2.5 ULN; Albumin < 2 g/dL; GGT > 2.5 ULN if Alkaline Phostphatase >2.5 ULN – Renal lab values: Creatinine > 1.5 ULN – Other severe acute or chronic medical condition that may increase the risk associated with study participation or investigational product administration

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ImaginAb, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Neeta Pandit-Taskar, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.